targeted therapy

41 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.

Section: newsJun 12, 2026

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

targeted therapy

Latest news

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

KRAS-Driven CLDN18.2 O-GlcNAcylation Promotes Pancreatic Cancer Progression and Therapy Resistance

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

Mapping the Escape: How Spatial Transcriptomics Reveals the Complex Resistance Landscape in HER2-Positive Gastric Cancer

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

Tinengotinib Offers a Potential Breakthrough for FGFR-Inhibitor Resistant Cholangiocarcinoma

Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial

Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial

Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025